News
Dr. Hassan Moeini
Iguana BioTechnology GmbH Welcomes Dr. Hassan Moeini, as the Head of Immunology
[Munich, 2/12/2024] - Iguana BioTechnology is pleased to announce the addition of Dr. Hassan Moeini to its team as the Head of Immunology. Dr. Moeini brings with him a wealth of experience in Vaccinology, having previously served as Project Leader at one of the excellent universities in Munich, where he made substantial contributions to the development of various vaccine platforms.
In his career, Dr. Moeini showcased profound expertise in immunology, microbiology, and virology, making him a valuable asset to our company's endeavors in the field of developing a therapeutic vaccine against Helicobacter pylori. His extensive knowledge spans different vaccine and nanoparticle technologies, aligning perfectly with our requirements at Iguana BioTechnology GmbH.
"We are thrilled to welcome Hassan to our team," said Dr. Behnam Kalali, CSO of Iguana Biotech. "His proven track record in vaccine development and deep understanding of immunological principles will undoubtedly bolster our efforts to innovate in this critical area."
In his new role, Dr. Moeini will spearhead immunological initiatives and continue advancing our vaccine candidates and nanoparticle research at Iguana Biotechnology.
Please join us in extending a warm welcome to Dr. Hassan Moeini as he embarks on this exciting journey with Iguana BioTechnology.
Successful funding of Iguana Biotechnology, project “Therapeutical vaccine against Helicobacter pylori”.
ACT-21 receives BMBF funding amounting to 1.65 Mio. EUR. Next milestone “ready for clinical phase I at the end of 2025”.
“KMUi-Biomedicine-2” to continue the development of a therapeutic vaccine (ACT21) against Helicobacter pylori.
Helicobacter pylori is the most common bacterial infection in the world. 50% of the world population is infected. The infection is associated with various gastrointestinal disorders, including chronic gastritis, peptic ulcers and stomach cancer. The bacterium is classified as a carcinogen pathogen of class I by the WHO. Early and successful treatment of the infection is an effective prevention to reduce new cases of gastric cancer.
The funding will enable us to accelerate our research efforts and invest in state-of-the-art services and technologies. We will reach status “Ready for Clinical Phase I” in the next 24 months.
We express our deepest gratitude to the Federal Ministry of Education and Research for recognizing the potential impact of our project for their commitment to fostering advancements in biomedicine addressing unmet medical needs.
This grant not only propels our company to the forefront of innovative research in developing a reliable therapeutic vaccine against Helicobacter pylori but also contributes to the broader mission of improving global healthcare.
Funding code (Förderkennzeichen): 16LW0474